Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

370 ARTÍCULOS , VIENDO DEL 241 AL 255

Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease

Li Q, He S, Chen Y, Feng F, Qu W, Sun H.

Eur J Med Chem. 2018 Oct 5;158:463-477. doi: 10.1016/j.ejmech.2018.09.031. Epub 2018 Sep 13.

DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective

Pathak A, Rohilla A, Gupta T, Akhtar MJ, Haider MR, Sharma K, Haider K, Yar MS.

Eur J Med Chem. 2018 Oct 5;158:559-592. doi: 10.1016/j.ejmech.2018.08.093. Epub 2018 Sep 11.

An evaluation of memantine ER + donepezil for the treatment of Alzheimer's disease

Calhoun A, King C, Khoury R, Grossberg GT.

Expert Opin Pharmacother. 2018 Oct;19(15):1711-1717. doi: 10.1080/14656566.2018.1519022. Epub 2018 Sep 23.

Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study

Nagata T, Shinagawa S, Nakajima S, Mimura M, Shigeta M.

J Alzheimers Dis. 2018;66(1):139-148. doi: 10.3233/JAD-180304.

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

Lawlor B, Segurado R, Kennelly S, Olde Rikkert MGM, Howard R, Pasquier F, Börjesson-Hanson A, Tsolaki M, Lucca U, Molloy DW, Coen R, Riepe MW, Kálmán J, Kenny RA, Cregg F, O'Dwyer S, Walsh C, Adams J, Banzi R, Breuilh L, Daly L, Hendrix S, Aisen P, Gaynor S, Sheikhi A, Taekema DG, Verhey FR, Nemni R, Nobili F, Franceschi M, Frisoni G, Zanetti O, Konsta A, Anastasios O, Nenopoulou S, Tsolaki-Tagaraki F, Pakaski M, Dereeper O, de la Sayette V, Sénéchal O, Lavenu I, Devendeville A, Calais G, Crawford F, Mullan M; NILVAD Study Group.

PLoS Med. 2018 Sep 24;15(9):e1002660. doi: 10.1371/journal.pmed.1002660. eCollection 2018 Sep.

Alzheimer's Disease: Special Focus on the Efficacy of Computer-Based Training Programs - A Mini-Review

Klimova B, Kuca K, Maresova P.

Curr Alzheimer Res. 2018;15(13):1213-1219. doi: 10.2174/1567205015666180925105902.

Global View on Alzheimer's Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer's Disease and Diabetes Mellitus

Klimova B, Kuca K, Maresova P.

Curr Alzheimer Res. 2018;15(14):1277-1282. doi: 10.2174/1567205015666180925110222.

Study partners: essential collaborators in discovering treatments for Alzheimer's disease

Largent EA, Karlawish J, Grill JD.

Alzheimers Res Ther. 2018 Sep 27;10(1):101. doi: 10.1186/s13195-018-0425-4.

Resveratrol and Alzheimer's disease. From molecular pathophysiology to clinical trials

Drygalski K, Fereniec E, Koryciński K, Chomentowski A, Kiełczewska A, Odrzygóźdź C, Modzelewska B.

Exp Gerontol. 2018 Nov;113:36-47. doi: 10.1016/j.exger.2018.09.019. Epub 2018 Sep 25.

Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics

Mullane K, Williams M.

Biochem Pharmacol. 2018 Dec;158:376-401. doi: 10.1016/j.bcp.2018.09.027. Epub 2018 Sep 29.

Alzheimer's disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality

Mullane K, Williams M.

Biochem Pharmacol. 2018 Dec;158:359-375. doi: 10.1016/j.bcp.2018.09.026. Epub 2018 Sep 29.

Effect of Physical Activity on the Progression of Alzheimer's Disease: The Clinical Research Center for Dementia of South Korea Study

Minn YK, Choi SH, Suh YJ, Jeong JH, Kim EJ, Kim JH, Park KW, Park MH, Youn YC, Yoon B, Choi SJ, Oh YK, Yoon SJ.

J Alzheimers Dis. 2018;66(1):249-261. doi: 10.3233/JAD-180333.

Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition

Grizzanti J, Corrigan R, Casadesus G.

J Alzheimers Dis. 2018;66(1):11-23. doi: 10.3233/JAD-180433.

Incidence and Prevalence of Antiepileptic Medication Use in Community-Dwelling Persons with and without Alzheimer's Disease

Sarycheva T, Taipale H, Lavikainen P, Tiihonen J, Tanskanen A, Hartikainen S, Tolppanen AM.

J Alzheimers Dis. 2018;66(1):387-395. doi: 10.3233/JAD-180594.

France Will No More Reimburse Available Symptomatic Drugs Against Alzheimer's Disease

Krolak-Salmon P, Dubois B, Sellal F, Delabrousse-Mayoux JP, Vandel P, Amieva H, Jeandel C, Andrieu S, Perret-Liaudet A.

J Alzheimers Dis. 2018;66(2):425-427. doi: 10.3233/JAD-180843.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias